Schedule 13D ownership disclosure

Prelude Therapeutics, Inc.

Common Stock, $0.0001 par value per share · CUSIP: 74065P101

Event date: 2025-06-12

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Baker Bros. Advisors LPReported CIK 0001263508

    Shares: 10,269,968.00 · Class: 23.5%

  • Baker Bros. Advisors (GP) LLCReported CIK 0001580575

    Shares: 10,269,968.00 · Class: 23.5%

  • Julian C. BakerReported CIK 0001087939

    Shares: 10,269,968.00 · Class: 23.5%

  • Felix J. BakerReported CIK 0001087940

    Shares: 10,269,968.00 · Class: 23.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-059474
Form type
SCHEDULE 13D/A
Filer
BAKER BROS. ADVISORS LP
CIK
CIK 1263508
Filed
Jun 13, 2025
Reporting period
Jun 12, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub